chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 12.0
Sex: F
Vaccine: FLU3, MNQ, TDAP
Symptoms: Injection site erythema, Injection site warmth
Clinical narrative: Case number PHHY2015US015305, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 550799) website on 03 Feb 2015, and with a follow up report received from QA department (351545) on 26 Feb 2015. This report refers to a 12-year-old female patient. Medical history included deletion of chromosome 4q.34.1 to 4q35.1. Current condition included polycystic kidney. On 12 Sep 2014, she was vaccinated with MENVEO (batch number: unknown) in the right arm along with FLUZONE (other manufacturer, batch number: DH937) in the right arm and BOOSTRIX (other manufacturer, batch number: 5SR2L) in the left arm. On 14 Sep 2014, she experienced 9-10 cm red and warm area at upper right arm. She visited the emergency room. She was given BENADRYL and the area was circled for reference. Later on the same date, she reported an increase in size of redness outside the circle. She received KEFLEX due to possibility of an infection. The outcome of the events reported as recovered. The events reported as non-serious. The causality of the events was not reported. Seriousness assessment of the events (vaccination site infection, erythema and warmth) was upgraded based on the information available in the source document. Since the batch number was not reported, a batch specific review could not be performed. Based on the Annual Product Review (APR) from 2010 to 2012, it was concluded that MENVEO manufacturing process was operated at a good level of overall control and the supporting systems are effective in supporting the compliant production, testing and supply processes for MENVEO. From this conclusion there was no reason or explanation to account for the reported adverse event. Follow up report received from QA department (351545) on 26 Feb 2015. Updated batch review report.
Age: 51.0
Sex: M
Vaccine: FLU3
Symptoms: Dizziness, Fall, Headache, Hypoaesthesia, Myalgia
Clinical narrative: Case number PHHY2015US017525, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS, reference number: 551560) website on 03 Feb 2015, with the follow-up information received from Quality Assurance Department on 20 Feb 2015. This report refers to a 51 year old male patient. Historical condition and concomitant medication were not reported. The patient was vaccinated with FLUVIRIN (batch number: unknown) in left arm on 13 Sep 2014. On 17 Sep 2014 (4 days after vaccination), he developed numbness, tingling, dizziness, seizure and he fell. He also experienced extreme vomiting, fever, muscle aches and headache. Final outcome of the events was reported as complete recovery. Events were reported as non-serious. Seriousness assessment of the event seizure was upgraded (medically significant) based on NV-Key event list and the event fall was upgraded (medically significant) based on the information available in the source document. Causality of the events was not reported. Upon FU from QA department, it was stated that the reported FLUVIRIN batch number U5017AA is not a valid batch number and no QA investigation would be performed. Follow-up information received from Quality Assurance Department on 20 Feb 2015: Updated QA comments.
Age: 51.0
Sex: M
Vaccine: FLU3
Symptoms: Paraesthesia, Pyrexia, Seizure, Vomiting
Clinical narrative: Case number PHHY2015US017525, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS, reference number: 551560) website on 03 Feb 2015, with the follow-up information received from Quality Assurance Department on 20 Feb 2015. This report refers to a 51 year old male patient. Historical condition and concomitant medication were not reported. The patient was vaccinated with FLUVIRIN (batch number: unknown) in left arm on 13 Sep 2014. On 17 Sep 2014 (4 days after vaccination), he developed numbness, tingling, dizziness, seizure and he fell. He also experienced extreme vomiting, fever, muscle aches and headache. Final outcome of the events was reported as complete recovery. Events were reported as non-serious. Seriousness assessment of the event seizure was upgraded (medically significant) based on NV-Key event list and the event fall was upgraded (medically significant) based on the information available in the source document. Causality of the events was not reported. Upon FU from QA department, it was stated that the reported FLUVIRIN batch number U5017AA is not a valid batch number and no QA investigation would be performed. Follow-up information received from Quality Assurance Department on 20 Feb 2015: Updated QA comments.
Age: 37.0
Sex: F
Vaccine: FLUC3
Symptoms: Erythema, Injection site pain, Injection site reaction, Purulent discharge, Skin lesion
Clinical narrative: Case number PHHY2015US016846, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 552020) website on 03 Feb 2015 and with the follow-up information received from Quality Assurance Department (reference number: 352568) on 19 Feb 2015. This report refers to a 37 years old female patient. Concurrent condition included environmental allergy. Concomitant medication included ibuprofen. She was vaccinated with FLUVIRIN (batch number: 161208) intramuscularly into right arm on 24 Oct 2014. On 26 Oct 2014, she experienced localized tenderness and pus drainage from injection site which was improving spontaneously. She developed small elevated lesion with 2 mm surrounding erythema, without induration that was consistent with minor staphylococcal skin infection. Final outcome of the events was condition unchanged. The case was assessed as non-serious. Seriousness assessment of staphylococcal skin infection was upgraded based on NVS-IMS list. Causality of the events was not reported. Upon FU from QA department, it stated that the reported batch number 161208 is not a valid batch number of FLUVIRIN, but the batch number provided is a FLUCELVAX batch. Hence suspect product recoded from FLUVIRIN to FLUCELVAX. Non-significant follow up information received from the quality assurance department (reference number: 352568) on 18 Feb 2015: Updated QA reference number only. Follow-up information received from Quality Assurance Department (reference number: 352568) on 19 Feb 2015: The suspect product recoded from FLUVIRIN to FLUCELVAX.
Age: 37.0
Sex: F
Vaccine: FLUC3
Symptoms: Staphylococcal skin infection
Clinical narrative: Case number PHHY2015US016846, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 552020) website on 03 Feb 2015 and with the follow-up information received from Quality Assurance Department (reference number: 352568) on 19 Feb 2015. This report refers to a 37 years old female patient. Concurrent condition included environmental allergy. Concomitant medication included ibuprofen. She was vaccinated with FLUVIRIN (batch number: 161208) intramuscularly into right arm on 24 Oct 2014. On 26 Oct 2014, she experienced localized tenderness and pus drainage from injection site which was improving spontaneously. She developed small elevated lesion with 2 mm surrounding erythema, without induration that was consistent with minor staphylococcal skin infection. Final outcome of the events was condition unchanged. The case was assessed as non-serious. Seriousness assessment of staphylococcal skin infection was upgraded based on NVS-IMS list. Causality of the events was not reported. Upon FU from QA department, it stated that the reported batch number 161208 is not a valid batch number of FLUVIRIN, but the batch number provided is a FLUCELVAX batch. Hence suspect product recoded from FLUVIRIN to FLUCELVAX. Non-significant follow up information received from the quality assurance department (reference number: 352568) on 18 Feb 2015: Updated QA reference number only. Follow-up information received from Quality Assurance Department (reference number: 352568) on 19 Feb 2015: The suspect product recoded from FLUVIRIN to FLUCELVAX.
Age: 61.0
Sex: M
Vaccine: FLU3
Symptoms: Computerised tomogram normal, Gait disturbance, Immunoglobulin therapy, Mobility decreased, Myelitis transverse
Clinical narrative: Case number PHHY2015US018188, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 552232) website on 03 Feb 2015 with a follow up information received from the quality assurance department on 20 Feb 2015. This report refers to 61-year-old male patient. He had no known medication allergies. Current conditions included allergy to bee stings and remote hypertension. He was vaccinated with FLUVIRIN (batch number: unknown) intramuscularly in the right arm on 24 Oct 2014. On 25 Oct 2014, about 24 hours after vaccination the patient experienced bilateral weakness in both arms and hands. On 26 Oct 2014, he was feeling more severe bilateral weakness of the upper extremities. He took two tablets of 325 mg Aspirin and waited for his wife to come home. He could barely walk to the car. His wife rushed him to the emergency room where the medical team did a stroke work up. He received tissue plasminogen activator. He was later found to be negative for stroke by CT scan and MRI test. It was reported that MRI test of the cervical spine revealed transverse myelitis. He received many rounds of intravenous steroids, intravenous immunoglobulin G, and was now on an oral prednisone taper. On 16 Nov 2014, his upper extremity range of motion improved significantly, but he still cannot move his left leg and had minimal movement of right leg. He was currently in a rehabilitation center and had a positive attitude about recovery. The patient was hospitalized for a duration of 10 days. The outcome of the events reported as not recovered. The causality of the events was not reported. Upon follow up receipt from quality assurance department on 20 Feb 2015, it was stated that the initially reported batch number 148525 was not a valid FLUVIRIN batch number and hence no investigation would be performed. Follow up information received from the quality assurance department on 20 Feb 2015: Batch investigation would not be performed as the reported batch number was not valid.
Age: 61.0
Sex: M
Vaccine: FLU3
Symptoms: Nuclear magnetic resonance imaging spinal abnormal
Clinical narrative: Case number PHHY2015US018188, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 552232) website on 03 Feb 2015 with a follow up information received from the quality assurance department on 20 Feb 2015. This report refers to 61-year-old male patient. He had no known medication allergies. Current conditions included allergy to bee stings and remote hypertension. He was vaccinated with FLUVIRIN (batch number: unknown) intramuscularly in the right arm on 24 Oct 2014. On 25 Oct 2014, about 24 hours after vaccination the patient experienced bilateral weakness in both arms and hands. On 26 Oct 2014, he was feeling more severe bilateral weakness of the upper extremities. He took two tablets of 325 mg Aspirin and waited for his wife to come home. He could barely walk to the car. His wife rushed him to the emergency room where the medical team did a stroke work up. He received tissue plasminogen activator. He was later found to be negative for stroke by CT scan and MRI test. It was reported that MRI test of the cervical spine revealed transverse myelitis. He received many rounds of intravenous steroids, intravenous immunoglobulin G, and was now on an oral prednisone taper. On 16 Nov 2014, his upper extremity range of motion improved significantly, but he still cannot move his left leg and had minimal movement of right leg. He was currently in a rehabilitation center and had a positive attitude about recovery. The patient was hospitalized for a duration of 10 days. The outcome of the events reported as not recovered. The causality of the events was not reported. Upon follow up receipt from quality assurance department on 20 Feb 2015, it was stated that the initially reported batch number 148525 was not a valid FLUVIRIN batch number and hence no investigation would be performed. Follow up information received from the quality assurance department on 20 Feb 2015: Batch investigation would not be performed as the reported batch number was not valid.
Age: 27.0
Sex: F
Vaccine: FLU3
Symptoms: Blood pressure increased, Chest discomfort, Flushing
Clinical narrative: Case number PHHY2015US018022, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS reference number: 552837) website on 03 Feb 2015 with a follow up information received from the quality assurance department on 20 Feb 2015. This report refers to a 27-year-old female patient. Historical conditions were not reported. No concomitant medication was reported. She was vaccinated with FLUVIRIN (batch number: unknown) into the left arm on 21 Oct 2014. On the same day after vaccination, the patient experienced chest heaviness and had a feeling of flushed. The patient's blood pressure (BP) was 158/100 and went to urgent care for medical evaluation. The final outcome of the events was recovered. The events were reported as non-serious. The events 'chest heaviness, BP 158/100 and feeling flushed' were internally upgraded as medically significant based on the information available in the source document. Causality was not reported. Upon follow up receipt from quality assurance department on 20 Feb 2015, it was reported that the initially reported batch number 143601 did not belong to a FLUVIRIN batch and hence no investigation would be performed. Follow up information received from the quality assurance department on 20 Feb 2015: Batch investigation could not be performed as the batch number was not valid.
Age: 51.0
Sex: F
Vaccine: FLU3
Symptoms: Bursitis, Lymphadenopathy
Clinical narrative: Case number PHHY2015US017491, is an initial spontaneous report received from the Vaccine Adverse Event Reporting System (VAERS, reference number: 553164) website on 03 Feb 2015 with a follow up information received from quality assurance department on 20 Feb 2015. This report refers to a 51 year old female patient. Historical condition and concomitant medication were not reported. The patient was vaccinated with FLUVIRIN (batch number: unknown) in right deltoid on 30 Oct 2014. On 03 Nov 2014 (4 days after vaccination), the patient claimed that she developed right shoulder bursitis and lymph enlargement. Final outcome of the event was unknown. Event was reported as non-serious. Seriousness assessment of right shoulder bursitis was upgraded (medically significant) based on NVS-IME list. Causality was not reported. Upon follow up receipt from quality assurance department on 20 Feb 2015, it was reported that the initially reported batch number 141401 was incomplete and therefore invalid for FLUVIRIN and hence it was not possible to perform a QA investigation. Follow up information received from quality assurance department on 20 Feb 2015: QA investigation would not be performed as the initially reported batch number was invalid.
Age: 6.0
Sex: M
Vaccine: VARCEL
Symptoms: Pyrexia
Clinical narrative: 103 fever.
Age: 21.0
Sex: F
Vaccine: MENB, MENB
Symptoms: Asthenia, Chills, Fatigue, Headache, Injection site pain
Clinical narrative: Chills, pain at injection site, headache, swollen lymph nodes, weakness, fatigue, muscle pain/soreness. It started at 6:00pm on March 3, 2015 and I am still dealing with these symptoms and it is 11:15 pm on March 4, 2015. No treatment.
Age: 21.0
Sex: F
Vaccine: MENB, MENB
Symptoms: Lymphadenopathy, Myalgia
Clinical narrative: Chills, pain at injection site, headache, swollen lymph nodes, weakness, fatigue, muscle pain/soreness. It started at 6:00pm on March 3, 2015 and I am still dealing with these symptoms and it is 11:15 pm on March 4, 2015. No treatment.
Age: 21.0
Sex: F
Vaccine: MENB, MENB
Symptoms: Chills, Contusion, Dizziness, Headache, Injection site pain
Clinical narrative: Chills, pain at injection site, headache, swollen lymph nodes, weakness, fatigue, muscle pain/soreness. It started at 6:00pm on March 3, 2015 and I am still dealing with these symptoms and it is 11:15 pm on March 4, 2015. No treatment.
Age: 21.0
Sex: F
Vaccine: MENB, MENB
Symptoms: Pyrexia, Skin discolouration
Clinical narrative: Chills, pain at injection site, headache, swollen lymph nodes, weakness, fatigue, muscle pain/soreness. It started at 6:00pm on March 3, 2015 and I am still dealing with these symptoms and it is 11:15 pm on March 4, 2015. No treatment.
Age: 0.19
Sex: F
Vaccine: DTPHEP
Symptoms: Crying, Emotional distress, Pain
Clinical narrative: Baby was in inconsolable pain after waking from nap. Provided her with infant Tylenol to ease pain and crying and she was feeling better the next morning.
Age: 1.24
Sex: F
Vaccine: IPV
Symptoms: Anaemia, Depression, Fatigue, Fungal infection, Gastrointestinal disorder
Clinical narrative: Chronic yeast infections, headaches, anemia, depression, allergies, leaky gut, fatigue, culminating in rheumatoid arthritis in hands, feet and suspected knees/hips. Connection made by doctor in the 80s. Only treatment that helped was a complete change of diet to reset gut. Arthritis went into remission.
Age: 1.24
Sex: F
Vaccine: IPV
Symptoms: Headache, Hypersensitivity, Rheumatoid arthritis
Clinical narrative: Chronic yeast infections, headaches, anemia, depression, allergies, leaky gut, fatigue, culminating in rheumatoid arthritis in hands, feet and suspected knees/hips. Connection made by doctor in the 80s. Only treatment that helped was a complete change of diet to reset gut. Arthritis went into remission.
Sex: F
Vaccine: HEPA
Symptoms: Seizure
Clinical narrative: This case was reported by a physician (subject's brother) via a sales representative and described the occurrence of seizure in a female subject of unspecified age who was vaccinated with HAVRIX (GlaxoSmithKline). In 2010, the subject received an unspecified dose of HAVRIX (administration site and route unknown, batch number not provided). In 2010, at an unspecified time after vaccination with HAVRIX, the subject experienced seizure. The subject was hospitalised. At the time of reporting, the outcome of the event was unspecified.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Activated partial thromboplastin time, Antibody test, Antinuclear antibody, Antiphospholipid antibodies, Antithrombin III
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Autonomic nervous system imbalance, Beta-2 glycoprotein antibody, Blood fibrinogen, Blood folate normal, Blood homocysteine
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Blood iron, Blood thyroid stimulating hormone normal, Borrelia test, C-reactive protein, Cardiolipin antibody
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Chronic fatigue syndrome, Coagulation factor V level, Cold agglutinins, Complement factor C3, Complement factor C4
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Condition aggravated, Cryoglobulins, Cytogenetic analysis, Electrophoresis protein, Enzyme level test
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Erythromelalgia, Full blood count, HIV test, HIV test negative, Hepatitis B virus test
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Hepatitis C virus test, Hypoaesthesia, Immunoglobulins, Metabolic function test, Nail disorder
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Nail ridging, Paraesthesia, Postural orthostatic tachycardia syndrome, Protein C, Prothrombin level
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Pruritus, Raynaud's phenomenon, Red blood cell sedimentation rate, Rheumatoid factor, Russell's viper venom time
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Sensory disturbance, Serum ferritin, Skin discolouration, Swelling, Tilt table test positive
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 29.0
Sex: F
Vaccine: FLU3
Symptoms: Vitamin B12 increased, Vitamin D decreased
Clinical narrative: This is a 33 year old female with a past medical history significant for Raynaud's Phenomenon (RP), erythromelalgia, Chronic Fatigue Syndrome (CFS), and dysautonomia, classic migraine, lumbar pain with radiculopathy, attention deficit hyperactivity disorder (ADHD), Post Traumatic Stress Disorder (PTSD) and mood disorders. She presented to clinic for evaluation of possible reaction to IIV or LAIV vaccine received during her service, most specifically doses received 10/2010 and 10/2011 as causality of her RP, erythromelalgia, CFS and/or dysautonomia, (which has subsequently more specifically diagnosed as Postural Tachycardia Syndrome [POTS]). The patient recalled developing purple discoloration with decreased sensation to feet and knees starting in late December 2010. She had performed a 17 hour sustained drive. She noted discoloration and numbness to her thighs extending distally below her knees, right more pronounced than left, and her feet were also discolored. She was seen in ER 28 Dec 2010 and was diagnosed with paresthesia and given instruction to follow up with her primary care provider. At subsequent visits with PCP and vascular surgery visit she reported symptoms spontaneously resolved until 5 January 2011, when they returned after exercising. She also stated symptoms were exacerbated by dependent position and resolve with elevation. She continued symptoms with discolored skin, swelling, itching and nail changes with concave ridges and dryness. She reported symptoms resolved spontaneously after cold weather ended. She denies any other acute symptoms post receipt of IIV. She has had extensive evaluation and consultation. She did not respond to usual treatment of Raynaud's disease. Consultation did not think she had Raynaud's but gave her a diagnosis of erythromelalgia. Over time she developed increasing fatigue, activity and postural intolerance. She was also given a diagnosis of Chronic fatigue syndrome, although she did not meet strict CDC criteria. She was evaluated for and demonstrated dysautonomia via tilt table testing but initially did not meet criteria for POTS; however on subsequent testing she did meet threshold criteria.
Age: 4.0
Sex: M
Vaccine: VARCEL
Symptoms: Herpes zoster, Rash, Varicella virus test positive
Clinical narrative: Herpes Zoster diagnosis in a two dose varicella vaccine recipient on 7/14/14. Treated with acyclovir. Painful rash in one dermatome. Lasted <4 weeks. Unknown history of disease.
Age: 11.0
Sex: F
Vaccine: MNQ, TDAP
Symptoms: Dysphagia, Throat irritation
Clinical narrative: Pt c/o of difficulty swallowing, frequent throat clearing.
Age: 31.0
Sex: M
Vaccine: MMR
Symptoms: Cardiac monitoring, Refusal of treatment by patient, Seizure like phenomena, Syncope
Clinical narrative: About 2 minutes after vaccine was given the patient had feelings of syncope followed by 15 seconds of seizure like activity. Patient was taken to ER for evaluation. Patient refused treatment and only allowed heart monitor to be put on and drank oral fluids.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site induration, Injection site swelling, Rash, Urticaria
Clinical narrative: Patient described the administration site as "red" and a "hard bump." The bump then spread as hives all over body. Patient reported rash and visited doctor on 3/4/15 and was treated with Benadryl.
Age: 64.0
Sex: F
Vaccine: FLU4
Symptoms: Musculoskeletal pain, Neck pain, Nuclear magnetic resonance imaging, Pain in extremity, Pyrexia
Clinical narrative: Fever, then extreme pain radiating into shoulder, neck and down arm to fingers.
Age: 64.0
Sex: F
Vaccine: FLU4
Symptoms: X-ray
Clinical narrative: Fever, then extreme pain radiating into shoulder, neck and down arm to fingers.
Age: 18.0
Sex: F
Vaccine: MENB
Symptoms: Abdominal pain upper, Back pain, Crying, Headache, Pain in extremity
Clinical narrative: Intense aches and pains: headache, stomachache, legs and arms hurt, back hurt.  Maybe fever but no thermometer was available.  Pain so bad that I cried for approx. 1/2 hr.  Took two ibuprofen and managed to stop crying after that.
Age: 21.0
Sex: F
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling, Injection site warmth
Clinical narrative: 1st VZV in 1998, 2nd VZV 02/25/2015. Pt called on 02/26/2015 c/o upper arm swollen at injection site. Also red & warm to the touch with itchy sensation. No s.o.b. or tightness to chest or swelling of tongue or lips. Tx advise cold packs to site, to reduce swelling & redness. Watch for additional swelling redness if increases or rash & itching increases seek help from PCP or ER since she has a severe allergy to Benadryl. May require additional intervention.
Age: 22.0
Sex: F
Vaccine: JEV1
Symptoms: Diarrhoea, Eye pruritus, Eye swelling, Nausea, Pyrexia
Clinical narrative: Diarrhea, Nausea, Fever, Swollen and Itchy Eyes.
Age: 19.0
Sex: F
Vaccine: MNQ
Symptoms: Abdominal pain upper, Asthenia, Chest discomfort, Chest pain, Dizziness
Clinical narrative: I felt sick just minutes after receiving the meningococcal vaccine (and also a TB skin test), both of which are required by my college. I believe the vaccine is what made me sick though. My chest started hurting and feeling tight. I had to sit down in a chair and my mother says that I passed out (and that my eyes roll in the back of my head). I was extremely woozy and had to keep my eye closed. I was given my inhaler and that seemed to help slow down my breathing about 10 minutes later. When I was able to walk, I was taken back to the rooms to wait for an available doctor to come see me. At this point, the breathing was better, but my muscles ached, I felt extremely tired, and my stomach also cramped. About 10-20 minutes later, all my symptoms subsided but I still felt a little weak. The doctor just told me to rest for the rest of the day and that this happens commonly around my age.
Age: 19.0
Sex: F
Vaccine: MNQ
Symptoms: Eye movement disorder, Fatigue, Loss of consciousness, Malaise, Myalgia
Clinical narrative: I felt sick just minutes after receiving the meningococcal vaccine (and also a TB skin test), both of which are required by my college. I believe the vaccine is what made me sick though. My chest started hurting and feeling tight. I had to sit down in a chair and my mother says that I passed out (and that my eyes roll in the back of my head). I was extremely woozy and had to keep my eye closed. I was given my inhaler and that seemed to help slow down my breathing about 10 minutes later. When I was able to walk, I was taken back to the rooms to wait for an available doctor to come see me. At this point, the breathing was better, but my muscles ached, I felt extremely tired, and my stomach also cramped. About 10-20 minutes later, all my symptoms subsided but I still felt a little weak. The doctor just told me to rest for the rest of the day and that this happens commonly around my age.